Plasma-Derived Therapies
North America · 3 shared keywords
Updated
Reviewed by Vidhi Upadhyay
North America Orphan Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Therapy Area, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$151.82 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $106.40 Bn | — | — |
| 2025 (base) | $116.72 Bn | +$10.32 Bn | — |
| 2026 (forecast) | $128.05 Bn | +$11.32 Bn | +9.7% |
| 2027 (forecast) | $140.47 Bn | +$12.42 Bn | +20.3% |
| 2028 (forecast) | $154.09 Bn | +$13.63 Bn | +32% |
| 2029 (forecast) | $169.04 Bn | +$14.95 Bn | +44.8% |
| 2030 (forecast) | $185.44 Bn | +$16.40 Bn | +58.9% |
| 2031 (forecast) | $203.42 Bn | +$17.99 Bn | +74.3% |
| 2032 (forecast) | $223.16 Bn | +$19.73 Bn | +91.2% |
| 2033 (forecast) | $244.80 Bn | +$21.65 Bn | +109.7% |
| 2034 (forecast) | $268.55 Bn | +$23.75 Bn | +130.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $116.72 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $268.55 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug type, therapy area and end user (see all) |
| Key players | Novartis AG, Sanofi, Roche, Takeda Pharmaceutical Company Ltd, Vertex Pharmaceuticals and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Orphan drugs treat rare diseases that affect small numbers of people, and get special incentives to encourage development.
Key segments of the orphan Drugs market include drug type (Biologics, Small Molecules and Gene and Cell Therapies) and therapy area (Oncology, Hematology and Neurology).
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the orphan Drugs market. More countries now have national rare disease plans.
Newborn genome screening, gene therapies and access programmes in emerging markets give the orphan Drugs market strong growth.
Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the orphan Drugs market.
The orphan Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the countries we cover here, medicines are approved by Health Canada (Canada)[1] and FDA (US)[2]. How care is paid for in these countries: provincial health insurance (Canada)[3] and Medicare and Medicaid (US)[4].
[1] Health Canada. Checked 14 Nov 2026.
[2] US Food and Drug Administration. Checked 14 Nov 2026.
[3] Health Canada. Checked 14 Nov 2026.
[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for orphan Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.
What doctors and scientists are doing in Orphan Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
North America · 3 shared keywords
North America · 2 shared keywords
North America · 2 shared keywords
North America · 1 shared keyword
North America · 1 shared keyword
North America · 1 shared keyword
Medical Devices · North America
Healthcare Services · North America
Healthcare Services · North America
Healthcare Services · North America
Healthcare Services · North America
Healthcare Services · North America